KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Edwards Lifesciences (EW) Receivables - Other (2016 - 2025)

Edwards Lifesciences has reported Receivables - Other over the past 17 years, most recently at $252.5 million for Q4 2025.

  • Quarterly results put Receivables - Other at $252.5 million for Q4 2025, up 113.44% from a year ago — trailing twelve months through Dec 2025 was $252.5 million (up 113.44% YoY), and the annual figure for FY2025 was $252.5 million, up 113.44%.
  • Receivables - Other for Q4 2025 was $252.5 million at Edwards Lifesciences, up from $199.5 million in the prior quarter.
  • Over the last five years, Receivables - Other for EW hit a ceiling of $252.5 million in Q4 2025 and a floor of $42.8 million in Q2 2022.
  • Median Receivables - Other over the past 5 years was $62.4 million (2023), compared with a mean of $89.4 million.
  • Biggest five-year swings in Receivables - Other: plummeted 47.87% in 2021 and later skyrocketed 266.49% in 2025.
  • Edwards Lifesciences' Receivables - Other stood at $82.7 million in 2021, then tumbled by 32.16% to $56.1 million in 2022, then grew by 0.89% to $56.6 million in 2023, then surged by 109.01% to $118.3 million in 2024, then skyrocketed by 113.44% to $252.5 million in 2025.
  • The last three reported values for Receivables - Other were $252.5 million (Q4 2025), $199.5 million (Q3 2025), and $205.6 million (Q2 2025) per Business Quant data.